September 9, 2015

Cooperation initiated with research group in Berlin for the planned clinical study

As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]

September 1, 2015

Follicum has completed toxicity studies

Follicum announced in March 2015  that they had started two larger toxicity studies to  add information to the two short time toxicity studies and  continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]

August 25, 2015

Drug substance ready for production

Follicum announce today that the synthesis of the peptide has been completed.  The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]

August 21, 2015

Half-year Report 2015

Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).

June 2, 2015

Cooperation agreement signed for clinical trials

Follicum announce today that a joint cooperation agreement has been signed with PolyPeptide Group and Recipharm AB in anticipation of the clinical trials which are estimated to start in the beginning of 2016. Read more here.

May 22, 2015

Financial Report Q1

Follicum’s financial report for the first quarter 2015 (1 January to 31 March) is now published. Click here to open the report (in Swedish).

May 4, 2015

Successful meeting with the Federal Institute for Drugs and Medical Devices in Germany

Follicum announces that they have had a successful scientific advisory meeting with BfArM  –  the Federal Institute for Drugs and Medical Devices in Germany. BfArM did not have any major questions or objections to the material that Follicum presented, which indicates that, given nothing unpredicted occurs in the tox studies, Follicum may start a clinical […]

April 30, 2015

Summary of Annual General Meeting

Yesterday, 29 April 2015, Follicum AB held their Annual General Meeting. The meeting resolved to adopt the presented income statement and balance  sheet as well as to dispose of the company’s profit according to the Board’s proposal in the Annual Report. Furthermore, the meeting decided that no dividend will be paid for fiscal year 2014. […]

April 8, 2015

Follicum’s Annual Report published

Follicum’s Annual Report for the financial year 2014 is now published in Swedish on the company’s website (Swedish version).  It is also available in Follicum’s office at Scheelevägen 22, Lund. For more information please contact: Dr Jan Alenfall, CEO Follicum AB Tel +46 46 19 21 97 Email